We could not find any results for:
Make sure your spelling is correct or try broadening your search.
VANCOUVER, British Columbia, Sept. 06, 2024 (GLOBE NEWSWIRE) -- ANORTECH INC. (“AnorTech” or the “Company”) (TSX Venture Exchange “ANOR”; OTC “HUDRF”) has granted incentive stock options under...
VANCOUVER, British Columbia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- ANORTECH INC. (“AnorTech” or the “Company”) (TSX Venture Exchange “ANOR”; OTC “HUDRF”) is pleased to announce that it has completed...
Acquisition to Strengthen Transplant and Oncology Businesses CAMBRIDGE, Mass. and VANCOUVER, B.C., Nov. 7 /PRNewswire-FirstCall/ -- Genzyme Corporation (NASDAQ:GENZ) and AnorMED Inc. (Nasdaq:...
CAMBRIDGE, Mass. and VANCOUVER, B.C., Nov. 7 /PRNewswire-FirstCall/ -- Genzyme Corporation (NASDAQ:GENZ) and AnorMED Inc. (Nasdaq: ANOR; TSX: AOM) announced today the expiration of the waiting...
AnorMED Board Recommends Shareholders Accept Genzyme Offer LANGLEY, BC, Nov. 3 /PRNewswire-FirstCall/ -- AnorMED Inc. ("AnorMED" or the "Company") (NASDAQ:ANOR; TSX:AOM) today released its...
VANCOUVER, Oct. 23 /PRNewswire-FirstCall/ -- AnorMED Inc. (NASDAQ:ANOR; TSX:AOM) today announced that it has completed enrollment in the second pivotal Phase III clinical trial evaluating its...
Genzyme to Gain Late-Stage Transplantation Product Candidate VANCOUVER, BC, and CAMBRIDGE, MA, Oct. 17 /PRNewswire-FirstCall/ -- Genzyme Corporation (NASDAQ:GENZ) and AnorMED Inc. (Nasdaq: ANOR;...
Millennium has the right to match Genzyme's 'superior proposal' VANCOUVER, Oct. 11 /PRNewswire-FirstCall/ -- AnorMED Inc. ("AnorMED" or "the Company") (NASDAQ:ANOR; TSX:AOM) announced that it...
Millennium has the right to match Genzyme's 'superior proposal' VANCOUVER, Oct. 11 /PRNewswire-FirstCall/ -- AnorMED Inc. ("AnorMED" or "the Company") (NASDAQ:ANOR; TSX:AOM) announced that it...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.025 | 0.025 | 0.025 | 6850 | 0.025 | CS |
4 | 0 | 0 | 0.025 | 0.03 | 0.025 | 7775 | 0.02551449 | CS |
12 | 0 | 0 | 0.025 | 0.035 | 0.02 | 71614 | 0.02752647 | CS |
26 | -0.005 | -16.6666666667 | 0.03 | 0.04 | 0.02 | 76874 | 0.02607704 | CS |
52 | -0.005 | -16.6666666667 | 0.03 | 0.05 | 0.02 | 68670 | 0.02766933 | CS |
156 | -0.005 | -16.6666666667 | 0.03 | 0.05 | 0.02 | 68670 | 0.02766933 | CS |
260 | -0.005 | -16.6666666667 | 0.03 | 0.05 | 0.02 | 68670 | 0.02766933 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions